| Document Date: 2013-11-04 05:32:28
Open Document File Size: 79,72 KBShare Result on Facebook
City Ghent / Breda / / Company arGEN / Seventure Partners / Forbion Capital Partners / PMV / Omnes Capital / Thuja Capital / BioGeneration Ventures / / Country Belgium / Netherlands / / Currency USD / EUR / / / Event Funding / FDA Phase / / IndustryTerm blue-chip / / MedicalCondition cancers / Kawasaki disease / rheumatoid arthritis / e.g. myasthenia gravis / immune thrombocytopenic purpura / systemic lupus / autoimmune diseases / / Organization Erasmus Biomedical Fund / / Person Tim Van Hauwermeiren / Debbie Allen / Chris De Jonghe / / / Position CEO / leader / OrbiMed Advisors / Chief Executive Officer / Group Manager / Manager Venture Capital / Director / Business Development / / Product ARGX-113 / / Technology ABDEG™ technology / antibodies / /
SocialTag |
arGEN-X raises EUR 5 million from PMV in extension of EUR 32.5 million series B Funds to advance ARGX-113, a novel antibody fragment approach to promote degradation and clearance of disease-causing autoantibodies, toward